SLNO possible move up comingGaps consistently close on SLNO. We are due for major gap close soon possible 2x to 3x. Massive buying including insiders.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.00 EUR
−35.32 M EUR
0.00 EUR
32.11 M
About Soleno Therapeutics, Inc.
Sector
CEO
Anish Bhatnagar
Headquarters
Redwood City
Website
Founded
1999
FIGI
BBG00GX8QK70
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
SLNO - Long Setup Lots of insider buying in June/July last year at $1.65-2.14. Big % and $ size. Possible entry above 1.20, Stop signal 1.07, Target 1 1.47, Target 2 Momentum. Small option chain but options available.
BIG RISK/REWARD ON SLNODear Traders,
As you can in the chart, SLNO is in the weekly support level, I expect launching toward the targets on the chart very soon.
*** This is not a financial advice, I'm still a beginner trying to share my Road here.
Than you.
SLNO to the Moon then MarsMarket Cap is so small that any Hedge Fund will pump this until trading bots start auto investing. When that happens we can see this stock close to $4.00 then reaching $8.00 based on momentum and FDA approval news.
Just my opinion, not investing advise, trade at your own risk
SLNO - Extreme Oversold Territory Going Long...SLNO - took a dive when the FDA demanded more testing of their latest drug. They are working on that and I suspect that we will see a retrace to 2.32 and possible sideways consolidation as the bulls sheepishly return to this little gem. I'm gonna run towards this as the bulls are running away. Be g
SLNO - Long Setup Watch for break of 2.78. Stop signal 2.47. LOTS of insider buying in June/July 2020. Big $ and Big % . First target 3.27. Second target momentum.
inverse head and shoulders (complex)reversal pattern at an ice line. confirmed breakout w/ a backtest. if this level of the neckline holds you'll see bullish div. on the 4hr. targeting the gap fill w a stop just below the previous low is 4:1 r/r. i picked a couple other peaks for targets beyond that. lil low on volume so position
Soleno Therapeutics, Inc. (SLNO) __NASDAQPrices of Interest 🧐🤔:
$1.96
$2.37
$2.62
Profit prices to consider 🧐🤔:
$4.58
SLNO: Buying the Dip, BullishFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, SLNO (which I been watching for a while), caught my interest again. I think today given the price decrease and retracement expectancies, it currently looks lik
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SOLENO THERAPEUT. DL-,001 stocks are traded under the ticker 6XC.
We've gathered analysts' opinions on SOLENO THERAPEUT. DL-,001 future price: according to them, 6XC price has a max estimate of 86.77 EUR and a min estimate of 62.51 EUR. Watch 6XC chart and read a more detailed SOLENO THERAPEUT. DL-,001 stock forecast: see what analysts think of SOLENO THERAPEUT. DL-,001 and suggest that you do with its stocks.
Yes, you can track SOLENO THERAPEUT. DL-,001 financials in yearly and quarterly reports right on TradingView.
SOLENO THERAPEUT. DL-,001 is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
6XC earnings for the last quarter are −1.64 EUR per share, whereas the estimation was −0.54 EUR resulting in a −202.48% surprise. The estimated earnings for the next quarter are −0.99 EUR per share. See more details about SOLENO THERAPEUT. DL-,001 earnings.
SOLENO THERAPEUT. DL-,001 revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
6XC net income for the last quarter is −68.81 M EUR, while the quarter before that showed −20.40 M EUR of net income which accounts for −237.27% change. Track more SOLENO THERAPEUT. DL-,001 financial stats to get the full picture.
No, 6XC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 42.00 employees. See our rating of the largest employees — is SOLENO THERAPEUT. DL-,001 on this list?
Like other stocks, 6XC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOLENO THERAPEUT. DL-,001 stock right from TradingView charts — choose your broker and connect to your account.